Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 6/20 | 0.59 |
| ▸ | TOP1 | P11387 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | RRM1 | P23921 | 2/20 | 0.49 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coh-29 SCHEMBL31436912 | 0.94 | PLTP (0.61) | PLTPTOP1ADORA2ARRM1RRM2B | |
| Coh-29 SCHEMBL29424344 | 0.94 | PLTP (0.61) | PLTPTOP1ADORA2ARRM1RRM2B | |
| Coh-29 SCHEMBL10036527 | 0.94 | PLTP (0.61) | PLTPTOP1ADORA2ARRM1RRM2B | |
| SCHEMBL10002075 | 0.81 | PLTP (0.86) | PLTPTOP1RRM1RRM2BKMT2A | |
| SCHEMBL2753294 | 0.79 | ADORA3 (0.74) | ADORA2AADORA1ADORA3KMT2ASMN1; SMN2 | |
| SCHEMBL235268 | 0.77 | ADORA3 (0.76) | ADORA2AADORA1ADORA3KMT2ASMN1; SMN2 | |
| SCHEMBL2753581 | 0.77 | ADORA2A (0.61) | ADORA2AADORA1ADORA3KMT2ASMN1; SMN2 | |
| SCHEMBL12802354 | 0.77 | L3MBTL1 (0.61) | ADORA1ADORA3KMT2ASMN1; SMN2HPGD | |
| SCHEMBL10002071 | 0.76 | PLTP (0.63) | PLTPTOP1RRM1RRM2BMAPT | |
| SCHEMBL918012 | 0.76 | ADORA2A (0.64) | ADORA2AADORA1ADORA3KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| US-9796692-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2017-05-18 | — | — | US | disclosed |
| US-9598385-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2016-05-05 | — | — | US | disclosed |
| US-9126960-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150087844-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2015-03-26 | — | — | US | disclosed |
| US-RE45020-E1 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2014-07-15 | — | — | US | disclosed |
| US-8372983-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087844-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885TOP1 1029/4885ADORA2A 3257/4885 |
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885TOP1 1029/4885ADORA2A 3257/4885 |
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885TOP1 1029/4885ADORA2A 3257/4885 |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885TOP1 1029/4885ADORA2A 3257/4885 |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885TOP1 1029/4885ADORA2A 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.